USA flag logo/image

An Official Website of the United States Government

Predictive value of inter-alpha inhibitors in sepsis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66538
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
GM068171
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PROTHERA BIOLOGICS, LLC
551 Warren Avenue EAST PROVIDENCE, RI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Predictive value of inter-alpha inhibitors in sepsis
Agency: HHS
Contract: 1R43GM068171-01
Award Amount: $131,233.00
 

Abstract:

DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor as a novel predictive marker for adult and newborn sepsis. IaIp are natural serine protease inhibitors found in relatively high concentration in human adult and newborn plasma (ranges between 600-1200 mg/L). IaIp have been implicated to play roles in inflammation, wound healing and cancer metastasis. The high level of IaIp circulating normally in plasma indicates that the proteins are essential for life and no person with complete absence of IaIp has ever been detected. Our preliminary results demonstrate a significant decrease of plasma IaIp levels in plasma of adult patients with severe sepsis and septic shock and the decrease correlates with the mortality suggesting the potential clinical utility of IaIp as a predictive marker in sepsis. A similar decrease of IaIp levels was found also in clinically proven neonatal sepsis. Furthermore, in our animal studies using a polymicrobial sepsis rat model of cecal ligation and puncture (CLP), we have demonstrated the beneficial effects of IaIp in maintaining hemodynamic stability, preventing organ injury, and improving survival during the progression of sepsis in adult animals. Taken together, the data strongly suggest the involvement of IaIp in the pathogenesis of sepsis. In this Phase I application, we will develop a standardized and validated immunoassay that is reliable and capable of accurately determining IaIp levels in biological fluids. This validated assay will be used to confirm our initial findings that IaIp levels in plasma constitute a valuable diagnostic, prognostic and theranostic marker for adult and neonatal sepsis.

Principal Investigator:

Yowpin Lim
4014382949
YOW-PIN_LIM_MD@BROWN.EDU

Business Contact:

Yow-pin Lin
4013012056
YOW-PIN_LIM_MD@BROWN.EDU
Small Business Information at Submission:

PROTHERA BIOLOGICS, LLC
PROTHERA BIOLOGICS, LLC 87 WALMER AVE EAST PROVIDENCE, RI 02914

EIN/Tax ID: 710868235
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No